This Article Full Text Full Text (PDF) All Versions of this Article: 107/23/2884    most recent 01.CIR.0000077530.53367.E9v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anand, S. S. Articles by Hirsh, J. Search for Related Content PubMed PubMed Citation Articles by Anand, S. S. Articles by Hirsh, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID HEPARIN Related Collections Acute coronary syndromes Arterial thrombosis Other anticoagulants Anticoagulant mechanisms

(Circulation. 2003;107:2884.)
© 2003 American Heart Association, Inc.

Clinical Investigation and Reports

Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin

Sonia S. Anand, MD, MSc, FRCP(c); Salim Yusuf, DPhil, FRCP; Janice Pogue, MSc; Jeffrey S. Ginsberg, MD, FRCP(c); Jack Hirsh, MD, FRCP(c), on Behalf of the Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators

From the Population Health Research Institute (S.S.A., S.Y., J.P.) and Henderson Research Centre (J.S.G., J.H.), McMaster University, Hamilton, Canada, and the Divisions of Cardiology and Thrombosis, Department of Medicine (S.S.A., S.Y., J.P., J.S.G., J.H.), McMaster University, Hamilton, Canada.

Correspondence to Sonia S. Anand, McMaster Clinic–Population Health Section, 237 Barton St E, Hamilton, Ontario L8L 2X2, Canada. E-mail anands{at}mcmaster.ca

Background— Antithrombotic therapy with intravenous heparin in conjunction with aspirin reduces negative cardiovascular (CV) outcomes in patients with acute coronary syndromes. The need for a therapeutic range with the activated partial thromboplastin time (APTT) has not been validated in patients with arterial thrombosis who receive heparin. Therefore, it is unclear whether there is an association between recurrent CV events and low APTT values and between bleeding and high APTT values.

Methods and Results— We examined the relationship between the APTT and recurrent cardiovascular events and bleeding among 5058 patients with an acute coronary syndrome without ST elevation who received intravenous heparin in the OASIS-2 trial. The increase in relative risk of recurrent CV events was 1.54 (95% CI 1.10 to 2.15; P=0.01) among patients with APTT values <60 seconds compared with patients with APTT values ≥60 seconds. When patients had persistently subtherapeutic APTT values for more than 48 hours, the increase in relative risk of a recurrent CV event was 1.84 (95% CI 1.25 to 2.70). Higher APTT values were associated with bleeding; for every 10-second increase in the APTT, the probability of major bleeding was increased by 7% (95% CI 3% to 11%; P=0.0004).

Conclusions— In patients with acute coronary syndromes without ST elevation who are treated with intravenous heparin, our findings justify regular APTT monitoring to minimize recurrent ischemic events and bleeding.

Key Words: heparin • thrombosis • coronary disease

This article has been cited by other articles:

				R. Schreiber Low-molecular-weight heparin vs unfractionated heparin in acute coronary syndromes. JAMA, May 24, 2006; 295(20): 2353 - 2353. [Full Text] [PDF]

				K. W. Mahaffey and S. G. Goodman Low-Molecular-Weight Heparin vs Unfractionated Heparin in Acute Coronary Syndromes--Reply JAMA, May 24, 2006; 295(20): 2353 - 2354. [Full Text] [PDF]

				B. K. Nallamothu, E. R. Bates, J. S. Hochman, C. B. Granger, V. Guetta, R. G. Wilcox, H. D. White, P. W. Armstrong, S. Savonitto, G. Jia, et al. Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial Eur. Heart J., August 1, 2005; 26(15): 1506 - 1512. [Abstract] [Full Text] [PDF]

				P. G. Steg and J.-M. Juliard Enoxaparin in non-ST segment elevation acute coronary syndromes: duration of therapy is essential to benefit Eur. Heart J., October 1, 2004; 25(19): 1667 - 1669. [Full Text] [PDF]

				M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 287S - 310S. [Abstract] [Full Text] [PDF]

				G. Montalescot, J.P. Collet, M.L. Tanguy, A. Ankri, L. Payot, R. Dumaine, R. Choussat, F. Beygui, V. Gallois, and D. Thomas Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin Circulation, July 27, 2004; 110(4): 392 - 398. [Abstract] [Full Text] [PDF]